

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
21 May 2004 (21.05.2004)

PCT

(10) International Publication Number
WO 2004/041280 A1

(51) International Patent Classification⁷: **A61K 31/4439**

University, Daehyeon-dong, Seodaemoon-ku, 120-750
Seoul (KR).

(21) International Application Number:

PCT/KR2003/002332

(74) Agent: **DARAE PATENT FIRM**; 10th Floor, KIPS,
647-9, Yeoksam-dong, Kangnam-ku, Seoul 135-980 (KR).

(22) International Filing Date:

3 November 2003 (03.11.2003)

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK,
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX,
MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD,
SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG,
US, UZ, VC, VN, YU, ZA, ZM, ZW.

(25) Filing Language:

Korean

(26) Publication Language:

English

(30) Priority Data:

10-2002-0067653

2 November 2002 (02.11.2002) KR

10-2003-0075511 28 October 2003 (28.10.2003) KR

(84) Designated States (*regional*): ARIPO patent (BW, GH,
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE,
SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA,
GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant and

(72) Inventor: **LEE, Kyung-Lim** [KR/KR]; Division of
Molecular Life Sciences, College of Pharmacy, Ewha
Womans University, Deahyeon-dong, Seodaemoon-ku,
120-750 Seoul (KR).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **LEE, Chul-Hee**
[KR/KR]; Otorhinolaryngology, Seoul National University
Hospital, Yeongeon-dong, Jongro-ku, 110-744 Seoul
(KR). **CHOI, Seung-Hee** [KR/KR]; Division of Molec-
ular Life Sciences, College of Pharmacy, Ewha Womans

Published:

— with international search report

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: COMPOSITION FOR PREVENTING SECRETION OF IMMUNOGLOBULIN E-DEPENDENT HISTAMINE RE-
LEASING FACTOR

(57) Abstract: The present invention relates to a composition for inhibiting the secretion of an immunoglobulin E (IgE)-dependent histamine-releasing factor, and pharmaceutical use thereof. The composition of the present invention contains a benzimidazolic compound having proton pump inhibitor activity, as an active ingredient. Furthermore, the composition of the present invention may contain at least one substance selected from the group consisting of fenoctimine, oleic acid, catechin, scopadulciol, pentagalloyl glucose, bufalin, and macrolide antibiotic bafilomycin and concanamycin, all having proton pump inhibitor activity, as an additional active ingredient or a single active ingredient. The composition of the present invention can be advantageously used as a pharmaceu-
tical composition for the prevention and treatment of various allergic diseases and malaria, which are caused by the IgE-dependent histamine-releasing factor.



WO 2004/041280 A1